A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing

Abstract excerpt

BACKGROUND: Guidelines for genetic testing for BRCA1 or BRCA2 stipulate that a personal or family history of cancer is necessary to be eligible for testing. Approximately 2% of Ashkenazi Jewish women carry a mutation, but to date population-based testing has not been advocated. Little is known about the relative yield of a conventional genetic testing programme versus a programme of widespread testing in a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to Cancer Genomics and Diagnostics
• Share to PARP inhibition in cancer therapy